6 recruiting, 5 not yet recruiting, 5 unknown, 2 active not recruiting. 19 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Recruiting 6, Not yet recruiting 5, Unknown 5, Active not recruiting 2, Withdrawn 1 |
| Phase 1 | 5 | Not yet recruiting 3, Active not recruiting 1, Recruiting 1 |
Follow PD-1 Inhibitor: new trials by email Literature Review of PD-1 Inhibitor trials Research Report on PD-1 Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 Tislelizumab, Becotatug Vedotin, Cisplatin - ESCC, Tislelizumab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 93 | 2026-04-01 | 2026-04-15 |
| Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer short-course radiotherapy that preserves tumor-draining lymph nodes - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 44 | 2026-02-01 | 2026-02-06 |
| Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer Nab-paclitaxel, Tislelizumab, endoscopic intervention - Renal Pelvic Carcinoma, Tislelizumab | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-11-25 | 2025-11-18 |
| LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study Low-dose Radiotherapy, Pucotenlimab, AG regimen - Pancreatic Cancer, PD-L1 | Phase 1 / Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 10 | 2025-09-30 | 2026-01-26 |
| Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases. - Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2025-09-01 | 2025-08-21 |
| Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders. - EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-21 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) - Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-17 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy - Ureteral Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-15 |
| Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed | Phase 1 / Phase 2 | Active not recruiting | Guangzhou Medical University | 39 | 2025-03-17 | 2026-10-13 |
| Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer fruquintinib + tislelizumab + FOLFOX - Gastric (Stomach) Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 44 | 2025-03-01 | 2025-03-12 |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy - Nasopharyngeal Neoplasms, PD-1 Inhibitor | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 208 | 2025-02-25 | 2025-07-01 |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma Pemigatinib, PD-1 Inhibitors - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2023-07-01 | 2023-06-22 |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma Serplulimab and Bevacizumab injection - Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 50 | 2023-01-10 | 2023-01-09 |
| Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin - Neoadjuvent, PD-1 Inhibitor | Phase 2 | Recruiting | Tang-Du Hospital | 114 | 2022-08-01 | 2023-08-23 |
| PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma PD-1 inhibitor+GP, GP - Nasopharyngeal Carcinoma, Neoadjuvant Therapy | Phase 2 | Active not recruiting | Guangxi Medical University | 150 | 2022-07-15 | 2025-12-11 |
| Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer Tislelizumab, Gemcitabine, Cisplatin - Urothelial Carcinoma Bladder, PD-1 Inhibitor | Phase 2 | Unknown | RenJi Hospital | 20 | 2022-06-01 | 2022-08-18 |
| Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Capecitabine - Radiotherapy, PD-1 Inhibitor | Phase 2 | Withdrawn | Fifth Affiliated Hospital, Sun Yat-Sen University | 2022-03-28 | 2026-09-23 | |
| PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure Camrelizumab, G-CSF - PD-1 Inhibitor, G-CSF | Phase 2 | Unknown | Sun Yat-sen University | 68 | 2022-01-24 | 2022-02-03 |
| Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma Regorafenib, PD-1 inhibitor - Hepatocellular Carcinoma, Regorafenib | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2021-10-01 | 2023-03-29 |
Nasopharyngeal Carcinoma (2) · Adenocarcinoma of Lung (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Digestive System Neoplasms (1) · Epstein-Barr Virus Infections (1) · Esophageal Squamous Cell Carcinoma (1) · Infections (1) · Meningeal Carcinomatosis (1) · Nasopharyngeal Neoplasms (1) · Pancreatic Neoplasms (1) · Pathologic Complete Response (1) · Rectal Neoplasms (1)
Neoplasms (12) · Neoplasms by Site (12) · Digestive System Diseases (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Digestive System Neoplasms (5) · Head and Neck Neoplasms (4) · Adenocarcinoma (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Nasopharyngeal Diseases (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3)
tislelizumab (5) · 130-nm albumin-bound paclitaxel (3) · Cisplatin (3) · Immune Checkpoint Inhibitors (3) · Lenalidomide (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Tenofovir (2) · camrelizumab (2) · Bevacizumab (1) · Capecitabine (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · HMPL-013 (1)
Tianjin Medical University Second Hospital (3) · The Affiliated Hospital of Xuzhou Medical University (2) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Fujian Cancer Hospital (1) · Guangxi Medical University (1) · Guangzhou Medical University (1) · Peking Union Medical College Hospital (1) · Peking University Cancer Hospital & Institute (1) · RenJi Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · Tang-Du Hospital (1) · The First Affiliated Hospital of Xiamen University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (15)
Hailong Hu, PhD (2) · Lei Zhang, PHD (1) · Wei Xue, PhD (1) · Xiaolong Yan, MD (1) · Zhenyu Pan, PhD,MD (1) · Zhigang MD Liu, PhD (1)